This chronic disease, which results in red, scaly and bleeding patches, can significantly affect patients' emotional well-being and self esteem.

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

PSORIASIS is no longer regarded as a single, uniform condition. Once classified primarily by visible lesions or severity, it ...

In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear ...

Every year on 29 October, World Psoriasis Day raises awareness of the 125 million people worldwide living with PsA ...

The results send a ‘clear, pragmatic message’ of IL-17 inhibition’s greater potency over IL-12/23 inhibition, an expert says.

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

New long-term data of the investigational therapy icotrokinra show that it is able to achieve site-specific clear or almost clear skin in patients with plaque psoriasis, according to results of the ...

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis ...

Subgroup analyses from one of the agent's pivotal trials showed that 29.5% of adolescents receiving icotrokinra achieved PASI 100, reflecting 100% improvement on the Psoriasis Area and Severity Index, ...

For symptoms of scalp psoriasis, home treatments like olive oil, oatmeal, and apple cider vinegar may provide relief and make ...

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favourable safety profile in difficult-to-treat scalp and genital psoriasis ...